PaxMedica, Inc. Common Stock (PXMD)
PaxMedica, Inc. is a biopharmaceutical company currently in the clinical development phase, dedicated to advancing anti-purinergic drug therapies (APTs). These innovative treatments are specifically designed to address complex neurological disorders presenting with stubborn and persistent symptoms. The company's primary investigative drug is PAX-101, an intravenous (IV) form of suramin, which is being explored for a variety of conditions. These include autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, post-COVID-19 syndrome (commonly known as "long COVID"), and human African trypanosomiasis. Furthermore, PaxMedica is also developing PAX-102, an intranasal version of suramin, intended for various neurological applications. The company, which was incorporated in 2018 and has its headquarters in Tarrytown, New York, previously operated as Purinix Pharmaceuticals LLC before rebranding to PaxMedica, Inc. in April 2020. It functions as a subsidiary of Tardimed Sciences LLC.
Sector: Biotechnology
Industry: Biotechnology
PaxMedica, Inc. Common Stock
- 0.0%
- 687
- 1.00
Float 10.69M · FMP free float
The cost to borrow PXMD shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- No fails on record for 16–31 Oct 2026.
Latest short interest settlements (today's share basis)
| Date | Shares short |
|---|---|
| Oct 30, 2026 | 687 sh |
| Oct 15, 2026 | 687 sh |
| Sep 30, 2026 | 687 sh |
| Sep 15, 2026 | 687 sh |
| Aug 31, 2026 | 687 sh |
A stock split executed inside this window; every settlement plotted has been carried onto today’s share basis, so the line does not step at the split.
The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.
Too few published sessions to show a reading in context.
FINRA's weekly alternative trading system (dark pool) volume for PXMD: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.
As of the Oct 30, 2026 FINRA settlement, 687 PXMD shares were sold short (0.01% of a 10.69M-share float, 1.00 days to cover).